PubRank

Shun Ishibashi

Author PubWeight™ 132.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endocrinol 2003 2.53
2 Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003 2.52
3 Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002 2.40
4 High cholesterol level is essential for myelin membrane growth. Nat Neurosci 2005 2.34
5 The critical role of neutral cholesterol ester hydrolase 1 in cholesterol removal from human macrophages. Circ Res 2010 1.92
6 Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 2002 1.86
7 Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005 1.85
8 The long-term effects of self-management education for patients with type 2 diabetes on glycemic control: response to Norris et al. Diabetes Care 2002 1.78
9 Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003 1.74
10 Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes 2004 1.68
11 Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J Biol Chem 2001 1.57
12 Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol Endocrinol 2003 1.49
13 Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha. J Lipid Res 2002 1.45
14 Cloning and characterization of a mammalian fatty acyl-CoA elongase as a lipogenic enzyme regulated by SREBPs. J Lipid Res 2002 1.43
15 Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 2005 1.42
16 Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb 2013 1.42
17 Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome 2010 1.40
18 Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome. Int Heart J 2017 1.39
19 Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. Diabetes Care 2003 1.38
20 Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice. Am J Physiol Endocrinol Metab 2003 1.30
21 p53 Activation in adipocytes of obese mice. J Biol Chem 2003 1.28
22 Identification of neutral cholesterol ester hydrolase, a key enzyme removing cholesterol from macrophages. J Biol Chem 2008 1.27
23 Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011 1.26
24 Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 2007 1.20
25 p53 involvement in the pathogenesis of fatty liver disease. J Biol Chem 2004 1.18
26 Identification of a novel member of the carboxylesterase family that hydrolyzes triacylglycerol: a potential role in adipocyte lipolysis. Diabetes 2006 1.17
27 FEEL-1 and FEEL-2 are endocytic receptors for advanced glycation end products. J Biol Chem 2002 1.17
28 SREBP-1-independent regulation of lipogenic gene expression in adipocytes. J Lipid Res 2007 1.16
29 Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis. Cell Metab 2009 1.16
30 Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012 1.16
31 Scavenger receptor expressed by endothelial cells I (SREC-I) mediates the uptake of acetylated low density lipoproteins by macrophages stimulated with lipopolysaccharide. J Biol Chem 2004 1.15
32 Lipolysis in the absence of hormone-sensitive lipase: evidence for a common mechanism regulating distinct lipases. Diabetes 2002 1.14
33 Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004 1.10
34 Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene. J Biol Chem 2003 1.06
35 Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler Thromb Vasc Biol 2011 1.06
36 RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res 2009 1.04
37 Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. J Biol Chem 2010 1.03
38 A single nucleotide polymorphism in the FADS1/FADS2 gene is associated with plasma lipid profiles in two genetically similar Asian ethnic groups with distinctive differences in lifestyle. Hum Genet 2010 1.03
39 Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb 2004 1.00
40 Relationship between exercise training-induced increase in insulin sensitivity and adiponectinemia in healthy men. Endocr J 2003 0.99
41 Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. Biochem Biophys Res Commun 2012 0.98
42 Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study. Diabetes Care 2012 0.98
43 Hormone-sensitive lipase is required for high-density lipoprotein cholesteryl ester-supported adrenal steroidogenesis. Mol Endocrinol 2003 0.98
44 A single bout of exercise at higher intensity enhances glucose effectiveness in sedentary men. J Clin Endocrinol Metab 2005 0.97
45 Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004 0.97
46 High mobility group protein-B1 interacts with sterol regulatory element-binding proteins to enhance their DNA binding. J Biol Chem 2005 0.97
47 Long-range negative correlation of glucose dynamics in humans and its breakdown in diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 2006 0.97
48 Regulatory SNP in the RBP4 gene modified the expression in adipocytes and associated with BMI. Obesity (Silver Spring) 2009 0.97
49 Components of metabolic syndrome and their combinations as predictors of cardiovascular disease in Japanese patients with type 2 diabetes. Implications for improved definition. Analysis from Japan Diabetes Complications Study (JDCS). J Atheroscler Thromb 2009 0.96
50 Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb 2011 0.95
51 Adrenal neutral cholesteryl ester hydrolase: identification, subcellular distribution, and sex differences. Endocrinology 2002 0.93
52 Waist circumference as a cardiovascular and metabolic risk in Japanese patients with type 2 diabetes. Obesity (Silver Spring) 2008 0.93
53 Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages. Proc Natl Acad Sci U S A 2004 0.93
54 A case of thymic enlargement in hyperthyroidism in a young woman. Thyroid 2004 0.93
55 Absence of hormone-sensitive lipase inhibits obesity and adipogenesis in Lep ob/ob mice. J Biol Chem 2004 0.92
56 The role of neutral cholesterol ester hydrolysis in macrophage foam cells. J Atheroscler Thromb 2011 0.92
57 The correlation of common carotid arterial diameter with atherosclerosis and diabetic retinopathy in patients with type 2 diabetes mellitus. Acta Diabetol 2011 0.92
58 Close association of severe hyponatremia with exaggerated release of arginine vasopressin in elderly subjects with secondary adrenal insufficiency. Eur J Endocrinol 2003 0.92
59 Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med 2007 0.91
60 Familial hypercholesterolemia. J Atheroscler Thromb 2013 0.91
61 Hormone-sensitive lipase is involved in hepatic cholesteryl ester hydrolysis. J Lipid Res 2008 0.90
62 Unilateral adrenalectomy improves insulin resistance and diabetes mellitus in a patient with ACTH-independent macronodular adrenal hyperplasia. Endocr J 2003 0.90
63 Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. Ophthalmology 2012 0.90
64 Sterol regulatory element-binding proteins activate insulin gene promoter directly and indirectly through synergy with BETA2/E47. J Biol Chem 2005 0.90
65 Targeting of neutral cholesterol ester hydrolase to the endoplasmic reticulum via its N-terminal sequence. J Lipid Res 2009 0.89
66 Elimination of cholesterol ester from macrophage foam cells by adenovirus-mediated gene transfer of hormone-sensitive lipase. J Biol Chem 2002 0.89
67 Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein. EMBO Rep 2007 0.88
68 Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb 2008 0.88
69 Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012. J Atheroscler Thromb 2013 0.88
70 Liver-specific deletion of 3-hydroxy-3-methylglutaryl coenzyme A reductase causes hepatic steatosis and death. Arterioscler Thromb Vasc Biol 2012 0.87
71 Effect of moderate exercise training on peripheral glucose effectiveness, insulin sensitivity, and endogenous glucose production in healthy humans estimated by a two-compartment-labeled minimal model. Diabetes 2004 0.87
72 Anti-atherosclerotic activity of triacsin C, an acyl-CoA synthetase inhibitor. J Antibiot (Tokyo) 2008 0.87
73 The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions: additional analysis from the Japan Diabetes Complications Study. Diabetes Care 2006 0.87
74 Diabetes mellitus. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. J Atheroscler Thromb 2013 0.86
75 Depot-specific expression of lipolytic genes in human adipose tissues--association among CES1 expression, triglyceride lipase activity and adiposity. J Atheroscler Thromb 2010 0.86
76 The LDL receptor is not necessary for acute adrenal steroidogenesis in mouse adrenocortical cells. Am J Physiol Endocrinol Metab 2006 0.86
77 Effects of hormone-sensitive lipase disruption on cardiac energy metabolism in response to fasting and refeeding. Am J Physiol Endocrinol Metab 2009 0.86
78 HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 2002 0.85
79 Macrophage lipoprotein lipase modulates the development of atherosclerosis but not adiposity. J Lipid Res 2013 0.85
80 Diabetic lipemia with eruptive xanthomatosis in a lean young female with apolipoprotein E4/4. Diabetes Res Clin Pract 2005 0.85
81 The lack of long-range negative correlations in glucose dynamics is associated with worse glucose control in patients with diabetes mellitus. Metabolism 2012 0.84
82 Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract 2010 0.84
83 Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine 2014 0.84
84 Cross-sectional association between BMI, glycemic control and energy intake in Japanese patients with type 2 diabetes. Analysis from the Japan Diabetes Complications Study. Diabetes Res Clin Pract 2007 0.84
85 Induction of ABCA1 by overexpression of hormone-sensitive lipase in macrophages. Biochem Biophys Res Commun 2008 0.83
86 Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. J Lipid Res 2006 0.83
87 Disruption of autosomal recessive hypercholesterolemia gene shows different phenotype in vitro and in vivo. Circ Res 2004 0.83
88 The relationship between urinary 8-hydroxydeoxyguanosine and metabolic risk factors in asymptomatic subjects. Med Princ Pract 2011 0.83
89 Comparative study of atherosclerotic parameters in Mongolian and Japanese patients with hypertension and diabetes mellitus. J Atheroscler Thromb 2010 0.83
90 Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. J Atheroscler Thromb 2013 0.83
91 Resistance to neointimal hyperplasia and fatty streak formation in mice with adrenomedullin overexpression. Arterioscler Thromb Vasc Biol 2002 0.82
92 Diagnostic criteria for dyslipidemia. J Atheroscler Thromb 2013 0.82
93 Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis. Hypertension 2008 0.82
94 Treatment B) drug therapy: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. J Atheroscler Thromb 2013 0.82
95 Treatment A) lifestyle modification: executive summary of the Japan Atherosclerosis Society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. J Atheroscler Thromb 2013 0.81
96 Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb 2008 0.81
97 Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in Brattleboro rats. Mol Ther 2003 0.81
98 Mutations in Japanese subjects with primary hyperlipidemia--results from the Research Committee of the Ministry of Health and Welfare of Japan since 1996--. J Atheroscler Thromb 2004 0.81
99 Interleukin-12p40 gene (IL-12B) polymorphism and Type 1 diabetes mellitus in Japanese: possible role in subjects without having high-risk HLA haplotypes. Diabetes Res Clin Pract 2005 0.81
100 Differences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2002 0.81
101 Diagnosis of atherosclerosis. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version. J Atheroscler Thromb 2013 0.81
102 Decrease in urinary excretion of aquaporin-2 associated with impaired urinary concentrating ability in diabetic nephropathy. Nephron 2002 0.80
103 Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. Transl Res 2006 0.80
104 Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. Endocr J 2010 0.80
105 Leptin inhibits and ghrelin augments hypothalamic noradrenaline release after stress. Stress 2008 0.80
106 Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury. Hypertension 2003 0.79
107 HLA-DR-DQ haplotype in rapid-onset type 1 diabetes in Japanese. Diabetes Care 2003 0.79
108 Neuromedin U facilitates oxytocin release from the pituitary via beta adrenoceptors. Neuroreport 2003 0.78
109 Index of glucose effectiveness derived from oral glucose tolerance test. Acta Diabetol 2012 0.78
110 Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus. Diabetes Res Clin Pract 2011 0.78
111 Coronary artery disease. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. J Atheroscler Thromb 2013 0.78
112 Hyperglycemia enhances VSMC proliferation with NF-kappaB activation by angiotensin II and E2F-1 augmentation by growth factors. Mol Cell Endocrinol 2002 0.78
113 Roles of immunoglobulin-like loops of junctional cell adhesion molecule 4; involvement in the subcellular localization and the cell adhesion. Genes Cells 2003 0.78
114 Other types of primary hyperlipoproteinemia(hyperlipidemia). Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. J Atheroscler Thromb 2013 0.78
115 New insights on the simultaneous assessment of insulin sensitivity and beta-cell function with the HOMA2 method: response to Caumo et al. Diabetes Care 2007 0.77
116 Requirement for hypertension and hyperlipidemia medication in U.S. and Japanese patients with diabetes. Am J Med 2004 0.77
117 Arterial wall elasticity measured using the phased tracking method and atherosclerotic risk factors in patients with type 2 diabetes. J Atheroscler Thromb 2013 0.77
118 Hepatic insulin sensitivity assessed by integrated model of hepatic and peripheral glucose regulation. Diabetes Technol Ther 2009 0.77
119 Current smoking status may be associated with overt albuminuria in female patients with type 1 diabetes mellitus: a cross-sectional study. Tob Induc Dis 2012 0.77
120 Management of type IIb dyslipidemia. J Atheroscler Thromb 2011 0.77
121 Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice. Hypertens Res 2008 0.77
122 The vascular renin-angiotensin system as a possible source of vascular inflammation in fructose-fed rats. Hypertens Res 2007 0.77
123 Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides. Metabolism 2006 0.77
124 The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients. Int J Vasc Med 2012 0.77
125 Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus. Endocr J 2013 0.77
126 The correlation between CVR-R and carotid atherosclerosis in type 2 diabetes mellitus patients with diabetic neuropathy. J Physiol Anthropol 2010 0.76
127 Background to discuss guidelines for control of plasma HDL-cholesterol in Japan. J Atheroscler Thromb 2012 0.76
128 The correlation between the cardio-ankle vascular index (CAVI) and serum amyloid A in asymptomatic Japanese subjects. Heart Vessels 2011 0.76
129 Metabolic syndrome. J Atheroscler Thromb 2013 0.76
130 Vasoactive intestinal peptide and cytokines enhance stem cell factor production from epidermal keratinocytes DJM-1. J Invest Dermatol 2002 0.75
131 Abrogation of neutral cholesterol ester hydrolytic activity causes adrenal enlargement. Biochem Biophys Res Commun 2010 0.75
132 Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Res Clin Pract 2004 0.75
133 Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus. Endocr J 2012 0.75
134 Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients. Pharmacol Rep 2012 0.75
135 Chronic kidney disease. J Atheroscler Thromb 2013 0.75
136 P-gp-induced modulation of regulatory volume increase occurs via PKC in mouse proximal tubule. Am J Physiol Renal Physiol 2002 0.75
137 Statements. J Atheroscler Thromb 2014 0.75
138 Obesity is a critical risk factor for worsening of glucose tolerance in a family with the mutant insulin receptor. Diabetes Care 2002 0.75
139 [Functions of enzymes involved in lipid metabolism]. Nihon Rinsho 2007 0.75
140 Apolipoprotein C-II deficiency with no rare variant in the APOC2 gene. J Atheroscler Thromb 2013 0.75
141 Other high-risk conditions. J Atheroscler Thromb 2013 0.75
142 Absolute risk of cardiovascular disease and lipid management targets. J Atheroscler Thromb 2013 0.75
143 Women. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version. J Atheroscler Thromb 2013 0.75
144 Urinary excretion of aquaporin-2 water channel in diabetic ketoacidosis. Nephron 2002 0.75
145 A kindred of familial acromegaly without evidence for linkage to MEN-1 locus. Endocr J 2002 0.75
146 Molecular analysis of a novel LCAT mutation (Gly179 → Arg) found in a patient with complete LCAT deficiency. J Atheroscler Thromb 2011 0.75
147 [Abnormalities of the enzymes involved in lipid metabolism]. Nihon Rinsho 2007 0.75
148 Regulation of hormone-sensitive lipase in islets. Diabetes Res Clin Pract 2006 0.75
149 Hormone-sensitive lipase deficiency suppresses insulin secretion from pancreatic islets of Lep ob/ob mice. Biochem Biophys Res Commun 2009 0.75
150 Urinary protein as a marker for systolic blood pressure reduction in patients with type 2 diabetes mellitus participating in an in-hospital diabetes education program. Hosp Pract (1995) 2011 0.75
151 Cerebrovascular diseases. J Atheroscler Thromb 2013 0.75
152 Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther 2016 0.75
153 [Acquired hypertriglyceridemia]. Nihon Rinsho 2013 0.75
154 The elderly. J Atheroscler Thromb 2013 0.75
155 [Common carotid arterial diameter and coronary artery disease]. Rinsho Byori 2011 0.75